Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -3.56% and Operating profit at -26.20% over the last 5 years
2
Positive results in Mar 26
3
With ROE of 3.76%, it has a fair valuation with a 1.13 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,329 Million (Mid Cap)
48.00
NA
1.70%
0.04
3.76%
1.43
Revenue and Profits:
Net Sales:
2,526 Million
(Quarterly Results - Jun 2026)
Net Profit:
217 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.66%
0%
8.66%
6 Months
21.65%
0%
21.65%
1 Year
34.89%
0%
34.89%
2 Years
133.59%
0%
133.59%
3 Years
-10.38%
0%
-10.38%
4 Years
-27.24%
0%
-27.24%
5 Years
-28.67%
0%
-28.67%
Dian Diagnostics Group Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.56%
EBIT Growth (5y)
-26.20%
EBIT to Interest (avg)
5.38
Debt to EBITDA (avg)
0.94
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
1.13
Tax Ratio
38.09%
Dividend Payout Ratio
485.44%
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
14.59%
ROE (avg)
19.22%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
1.81
EV to EBIT
23.99
EV to EBITDA
13.06
EV to Capital Employed
1.78
EV to Sales
1.21
PEG Ratio
0.24
Dividend Yield
1.35%
ROCE (Latest)
7.43%
ROE (Latest)
3.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
2,526.40
2,247.00
12.43%
Operating Profit (PBDIT) excl Other Income
441.90
321.90
37.28%
Interest
29.90
32.70
-8.56%
Exceptional Items
-6.00
2.10
-385.71%
Consolidate Net Profit
216.50
104.20
107.77%
Operating Profit Margin (Excl OI)
123.70%
85.70%
3.80%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 12.43% vs -11.20% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 107.77% vs 386.26% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,064.60
12,166.60
-17.28%
Operating Profit (PBDIT) excl Other Income
1,026.70
1,226.90
-16.32%
Interest
176.10
221.70
-20.57%
Exceptional Items
-74.40
-424.20
82.46%
Consolidate Net Profit
145.60
-169.20
186.05%
Operating Profit Margin (Excl OI)
45.00%
41.20%
0.38%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -17.28% vs -9.03% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 186.05% vs -129.09% in Dec 2024
About Dian Diagnostics Group Co. Ltd. 
Dian Diagnostics Group Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






